Paladin, I'm sure you are correct that many feel better about this company since the presentation. I would say everything that was said makes sense, I just find it hard to get too positive given whose saying it.

I too find it a bit strange that there isn't a line up of suitors for Apabetalone if the numbers shown in this presentation are even in the realm of realistic although perhaps some in pharma think that it will be a little harder for BoM2 to replicate BoM because as time passes standard of care is always improving thereby making potential margins for further improvement smaller. Although that is definitely a guess I'm not qualified to make, management on the other hand seems to like to live in some sort of fantasy world where time stands still and everyone is waiting for RVX. Another factor might perhaps be that buy/sell valuations vis a vis time to market and potential net benefit are too far apart now.  The CMC backlogs Don mentioned may also play a part in how long a potential purchaser was or might be willing to commit to essentially extend dead money if the price was too rich. Perhaps if a deal is made involving Zenith Epigentics a potential partner/purchaser might come to an agreement sooner with the prospect of potentially more immediate cash flow if the Zenith NUT Carcinoma program continues to progress so positively.

IMO there are a considerable number of variables but I think it is actually quite a positive sign that both Eversana and Cencora remain involved despite having to wait on receiving compensation.

Koo, although Don laid out a scenario where ZCC potentially sells off some of the RVX Preferred shares and all of ZEL, it seems to me (from this and other presentations) that management would be open to any deal structure that facilitates cash to fund BoM2. I think this is a good thing but I would hope that they would also consider the outright sale of both RVX and ZCC packaged together.  Even if it was at a somewhat larger discount to future value, I would prefer a sooner than later outright sale of everything where investors are paid directly for their shares in ZCC and RVX.  Again, if the numbers in the presentation are close to realistic one would think there would be enough room to make both buyer and seller's happy.

All JMO